Savara Reports Third Quarter 2024 Financial Results and Provides Business Update
Savara, Inc. (SVRA)
Last savara, inc. earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
savarapharma.com/investors/events-presentations
Company Research
Source: Business Wire
Recently Completed Pre-BLA Meeting with FDA for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)Company Plans to Initiate Biologics License Application (BLA) Rolling Submission by End of YearUpdates Guidance on MOLBREEVI BLA Submission Completion Date to End of 1Q 2025 from 1H 2025 – Intends to Request Priority ReviewExpects to Submit MOLBREEVI Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) by End of 2025With ~$219M in Cash and Short-Term Investments, the Company Believes it is Sufficiently Capitalized through 2Q 2027 LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2024 and provided a business update.“After a productive pre-BLA meeting with the FDA, we are working diligently to initiate a rolling submission for MOLBREEVI by the end of this year, with plans to
Show less
Read more
Impact Snapshot
Event Time:
SVRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SVRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SVRA alerts
High impacting Savara, Inc. news events
Weekly update
A roundup of the hottest topics
SVRA
News
- Savara Inc (NASDAQ: SVRA) had its price target lowered by analysts at HC Wainwright from $10.00 to $6.00. They now have a "buy" rating on the stock.MarketBeat
- Savara Announces Participation in Upcoming Healthcare Conferences [Yahoo! Finance]Yahoo! Finance
- Savara Inc (NASDAQ: SVRA) had its "in-line" rating re-affirmed by analysts at Evercore ISI. They now have a $5.00 price target on the stock, down previously from $7.00.MarketBeat
- Savara Announces Participation in Upcoming Healthcare ConferencesBusiness Wire
- Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference [Yahoo! Finance]Yahoo! Finance
SVRA
Earnings
- 11/12/24 - In-Line
SVRA
Sec Filings
- 11/12/24 - Form 4
- 11/12/24 - Form 10-Q
- 11/12/24 - Form SC
- SVRA's page on the SEC website